Annette Dam Fialla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Annette Dam Fialla has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Anette Drøhse Kjeldsen
Department of Oto-Rhino-Laryngology, Odense University Hospital, Odense, Denmark
4 shared publications - Aleksander Krag
Centre for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark
2 shared publications - Bryony Jones
VASCERN HHT Reference Centre, Imperial College Healthcare National Health Service Trust, London, UK
2 shared publications - Carlo Sabbà
Department of Interdisciplinary Medicine, University of Bari “Aldo Moro”, 70124 Bari, Italy
2 shared publications - Claire L. Shovlin
National Heart and Lung Institute, Imperial College London, London W12 0NN, UK
2 shared publications - David Lefroy
VASCERN HHT Reference Centre, Imperial College Healthcare National Health Service Trust, London, UK
2 shared publications
Latest Publications
- Open Access
Cytomegalovirus Infection and Lung Function in Liver Transplant Recipients: A Nationwide Cohort Study
Impaired lung function is more common among liver transplant recipients than the general population, but the pathogenesis is unknown. We investigated whether prior CMV infections are associated with impaired lung function in liver transplant recipients. We invited adult liver transplant recipients from The Danish Comorbidity in Liver Transplant Recipients study (DACOLT) for spirometry and collected data from systematic CMV screening for serostatus and DNAemia. Using linear and logistic regressions adjusted for age, sex, cumulative smoking, and use of inhalation medication, we assessed if prior CMV infections were associated with airflow limitation (FEV 1 /FVC < 0.7 and FEV 1 < 80% of expected) and FEV 1 . Of all eligible liver transplant recipients in Denmark, DACOLT included 600 (79%), and 356 fulfilled the substudy‐specific inclusion criteria. In adjusted models, pretransplant CMV seropositivity was not associated with either airflow limitation (aOR 2.18 [95% CI: 0.71–6.62]) or lower FEV 1 (adjusted β [a β ] = −60 [95% CI: −210 to 80] mL). The same applied to associations between prior CMV DNAemia and airflow limitation (aOR 0.91 [95% CI: 0.35–2.35]) as well as FEV 1 (a β = 30 [95% CI: −120 to 180] mL). This suggests limited clinical impact of CMV infection on posttransplant lung function in liver transplant recipients.
Open AccessCytomegalovirus Infection and Lung Function in Liver Transplant Recipients: A Nationwide Cohort Study
Impaired lung function is more common among liver transplant recipients than the general population, but the pathogenesis is unknown. We investigated whether prior CMV infections are associated with impaired lung function in liver transplant recipients. We invited adult liver transplant recipients from The Danish Comorbidity in Liver Transplant Recipients study (DACOLT) for spirometry and collected data from systematic CMV screening for serostatus and DNAemia. Using linear and logistic regressions adjusted for age, sex, cumulative smoking, and use of inhalation medication, we assessed if prior CMV infections were associated with airflow limitation (FEV 1 /FVC < 0.7 and FEV 1 < 80% of expected) and FEV 1 . Of all eligible liver transplant recipients in Denmark, DACOLT included 600 (79%), and 356 fulfilled the substudy‐specific inclusion criteria. In adjusted models, pretransplant CMV seropositivity was not associated with either airflow limitation (aOR 2.18 [95% CI: 0.71–6.62]) or lower FEV 1 (adjusted β [a β ] = −60 [95% CI: −210 to 80] mL). The same applied to associations between prior CMV DNAemia and airflow limitation (aOR 0.91 [95% CI: 0.35–2.35]) as well as FEV 1 (a β = 30 [95% CI: −120 to 180] mL). This suggests limited clinical impact of CMV infection on posttransplant lung function in liver transplant recipients.
- Open Access
- 6 October 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
Determinants of quality of life in hereditary haemorrhagic telangiectasia: the relative roles of bleeding, anaemia and visceral involvement
Background and aims: Hereditary haemorrhagic telangiectasia (HHT) is a multisystem vascular disorder characterised by recurrent bleeding and visceral arteriovenous malformations (AVMs). Although anaemia and reduced quality of life (QoL) are common, the relative contribution of disease manifestations to patient-perceived health status remains unclear. This study aimed to assess the prevalence of iron deficiency (ID) and anaemia and to evaluate the impact of disease manifestations on QoL and health utility in patients with HHT. Methods: In this cross-sectional cohort study, all known patients with HHT from two Danish regions were invited to participate. Participants underwent clinical assessment, laboratory testing and completion of the Epistaxis Severity Score (ESS), the Short Form-36 (SF-36) and the EQ-5D-5 L questionnaires. Visceral AVM data were obtained from routine clinical screening. Multivariable linear regression analyses were performed to identify factors independently associated with QoL and health utility. Results: A total of 152 patients were included. The prevalence of ID and anaemia was 20.3% and 19.1%, respectively. Most patients had no or mild epistaxis; however, higher ESS scores were independently associated with lower haemoglobin levels and increased odds of anaemia. In multivariable analyses, increasing ESS was significantly associated with lower SF-36 vitality and general health scores and reduced EQ-5D-5L index values. Iron deficiency was independently associated with lower health utility, whereas visceral AVMs were not independently linked to QoL outcomes. Conclusion: In this population-based HHT cohort, epistaxis severity was more strongly associated with impaired QoL and health utility than visceral organ involvement. These findings highlight the importance of systematic assessment and management of bleeding and iron deficiency in HHT.
- 6 October 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
Open AccessDeterminants of quality of life in hereditary haemorrhagic telangiectasia: the relative roles of bleeding, anaemia and visceral involvement
Background and aims: Hereditary haemorrhagic telangiectasia (HHT) is a multisystem vascular disorder characterised by recurrent bleeding and visceral arteriovenous malformations (AVMs). Although anaemia and reduced quality of life (QoL) are common, the relative contribution of disease manifestations to patient-perceived health status remains unclear. This study aimed to assess the prevalence of iron deficiency (ID) and anaemia and to evaluate the impact of disease manifestations on QoL and health utility in patients with HHT. Methods: In this cross-sectional cohort study, all known patients with HHT from two Danish regions were invited to participate. Participants underwent clinical assessment, laboratory testing and completion of the Epistaxis Severity Score (ESS), the Short Form-36 (SF-36) and the EQ-5D-5 L questionnaires. Visceral AVM data were obtained from routine clinical screening. Multivariable linear regression analyses were performed to identify factors independently associated with QoL and health utility. Results: A total of 152 patients were included. The prevalence of ID and anaemia was 20.3% and 19.1%, respectively. Most patients had no or mild epistaxis; however, higher ESS scores were independently associated with lower haemoglobin levels and increased odds of anaemia. In multivariable analyses, increasing ESS was significantly associated with lower SF-36 vitality and general health scores and reduced EQ-5D-5L index values. Iron deficiency was independently associated with lower health utility, whereas visceral AVMs were not independently linked to QoL outcomes. Conclusion: In this population-based HHT cohort, epistaxis severity was more strongly associated with impaired QoL and health utility than visceral organ involvement. These findings highlight the importance of systematic assessment and management of bleeding and iron deficiency in HHT.
- 7 April 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (4) , e264654
Decompensated liver failure due to portal hypertension as a result of hepatic arteriovenous malformations
Portal hypertension is usually seen because of liver cirrhosis, causing a plethora of symptoms such as ascites and oesophageal varices. However, altered hepatic vasculature can affect the portal venous pressure and thereby cause portal hypertension, giving rise to similar symptomology. This paper presents a case of recurring severe gastrointestinal (GI) bleeding, ascites and oesophageal varices in a patient with hepatic arteriovenous malformations (HAVM). Physical examination, liver biopsy, clinical imaging and genetic testing disproved hereditary haemorrhagic telangiectasia (HHT) and liver cirrhosis. Bevacizumab (BVZ) was initiated on the basis of experience from treating vascular malformations in HHT patients. The patient has not shown signs of GI bleeding since the initiation of BVZ. Genetic testing detected a mutation in the EPHB4 gene of previously unknown significance, but a connection with vascular malformations has been suggested in the literature. Collectively, this case calls for considering hepatic vascular malformations in patients with non-cirrhotic portal hypertension.
- 7 April 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (4) , e264654
Decompensated liver failure due to portal hypertension as a result of hepatic arteriovenous malformations
Portal hypertension is usually seen because of liver cirrhosis, causing a plethora of symptoms such as ascites and oesophageal varices. However, altered hepatic vasculature can affect the portal venous pressure and thereby cause portal hypertension, giving rise to similar symptomology. This paper presents a case of recurring severe gastrointestinal (GI) bleeding, ascites and oesophageal varices in a patient with hepatic arteriovenous malformations (HAVM). Physical examination, liver biopsy, clinical imaging and genetic testing disproved hereditary haemorrhagic telangiectasia (HHT) and liver cirrhosis. Bevacizumab (BVZ) was initiated on the basis of experience from treating vascular malformations in HHT patients. The patient has not shown signs of GI bleeding since the initiation of BVZ. Genetic testing detected a mutation in the EPHB4 gene of previously unknown significance, but a connection with vascular malformations has been suggested in the literature. Collectively, this case calls for considering hepatic vascular malformations in patients with non-cirrhotic portal hypertension.
- Open Access
- 1 January 2022
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 65 (1) , 104370
The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care
- 1 January 2022
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 65 (1) , 104370
Open AccessThe European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care
- Open Access
- 26 November 2020
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 15 (1) , 1-7
High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment
Background: This report addresses how patients with hereditary hemorrhagic telangiectasia (HHT) and high output cardiac failure (HOCF) due to hepatic vascular malformations, should be evaluated and could be treated. HHT is a genetic disorder, leading to vascular abnormalities with potentially serious clinical implications. In the liver, arteriovenous malformations occur in more than 70% of patients, but only about 8% present clinical symptoms such as HOCF with pulmonary hypertension and less commonly portal hypertension, biliary ischemia and hepatic encephalopathy.Results: Three female patients with HHT type 2 and HOCF caused by severe arteriovenous malformations in the liver are presented in this case series. The patients were seen at the HHT-Centre at Odense University Hospital. Treatment with either orthotopic liver transplantation (one patient) or bevacizumab (two patients) was initiated. All patients experienced marked symptom relief and objective improvement. New York Heart Association—class were improved, ascites, peripheral edema and hence diuretic treatment was markedly reduced or discontinued in all three patients. Bevacizumab also resulted in notable effects on epistaxis and anemia.Conclusion: Our findings substantiate the importance of identification of symptomatic arteriovenous malformations in the liver in patients with HHT. Bevacizumab may possibly, as suggested in this case series and supported by previous case studies, postpone the time to orthotopic liver transplantation or even make it unnecessary. Bevacizumab represents a promising new treatment option, which should be investigated further in clinical trials.
- 26 November 2020
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 15 (1) , 1-7
Open AccessHigh output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment
Background: This report addresses how patients with hereditary hemorrhagic telangiectasia (HHT) and high output cardiac failure (HOCF) due to hepatic vascular malformations, should be evaluated and could be treated. HHT is a genetic disorder, leading to vascular abnormalities with potentially serious clinical implications. In the liver, arteriovenous malformations occur in more than 70% of patients, but only about 8% present clinical symptoms such as HOCF with pulmonary hypertension and less commonly portal hypertension, biliary ischemia and hepatic encephalopathy.Results: Three female patients with HHT type 2 and HOCF caused by severe arteriovenous malformations in the liver are presented in this case series. The patients were seen at the HHT-Centre at Odense University Hospital. Treatment with either orthotopic liver transplantation (one patient) or bevacizumab (two patients) was initiated. All patients experienced marked symptom relief and objective improvement. New York Heart Association—class were improved, ascites, peripheral edema and hence diuretic treatment was markedly reduced or discontinued in all three patients. Bevacizumab also resulted in notable effects on epistaxis and anemia.Conclusion: Our findings substantiate the importance of identification of symptomatic arteriovenous malformations in the liver in patients with HHT. Bevacizumab may possibly, as suggested in this case series and supported by previous case studies, postpone the time to orthotopic liver transplantation or even make it unnecessary. Bevacizumab represents a promising new treatment option, which should be investigated further in clinical trials.
- Open Access
- 29 June 2020
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 15 (1) , 1-10
European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT)
Hereditary haemorrhagic telangiectasia (HHT) is a multisystemic vascular dysplasia inherited as an autosomal dominant trait. Approximately 10 % of patients have cerebral vascular malformations, a proportion being cerebral arteriovenous malformations (AVMs) and fistulae that may lead to potentially devastating consequences in case of rupture. On the other hand, detection and treatment related-risks are not negligible, and immediate. While successful treatment can be undertaken in individual cases, current data do not support the treatment of unruptured AVMs, which also present a low risk of bleeding in HHT patients. Screening for these AVMs is therefore controversial.Structured discussions, distinctions of different cerebrovascular abnormalities commonly grouped into an “AVM” bracket, and clear guidance by neurosurgical and neurointerventional radiology colleagues enabled the European Reference Network for Rare Vascular Disorders (VASCERN-HHT) to develop the following agreed Position Statement on cerebral screening:1) First, we emphasise that neurological symptoms suggestive of cerebral AVMs in HHT patients should be investigated as in general neurological and emergency care practice. Similarly, if an AVM is found accidentally, management approaches should rely on expert discussions on a case-by-case basis and individual risk-benefit evaluation of all therapeutic possibilities for a specific lesion.2) The current evidence base does not favour the treatment of unruptured cerebral AVMs, and therefore cannot be used to support widespread screening of asymptomatic HHT patients.3) Individual situations encompass a wide range of personal, cultural and clinical states. In order to enable informed patient choice, and avoid conflicting advice, particularly arising from non-neurovascular interpretations of the evidence base, we suggest that all HHT patients should have the opportunity to discuss knowingly brain screening issues with their healthcare provider.4) Any screening discussions in asymptomatic individuals should be preceded by informed pre-test review of the latest evidence regarding preventative and therapeutic efficacies of any interventions. The possibility of harm due to detection of, or intervention on, a vascular malformation that would not have necessarily caused any consequence in later life should be stated explicitly.We consider this nuanced Position Statement provides a helpful, evidence-based framework for informed discussions between healthcare providers and patients in an emotionally charged area.
- 29 June 2020
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 15 (1) , 1-10
Open AccessEuropean Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT)
Hereditary haemorrhagic telangiectasia (HHT) is a multisystemic vascular dysplasia inherited as an autosomal dominant trait. Approximately 10 % of patients have cerebral vascular malformations, a proportion being cerebral arteriovenous malformations (AVMs) and fistulae that may lead to potentially devastating consequences in case of rupture. On the other hand, detection and treatment related-risks are not negligible, and immediate. While successful treatment can be undertaken in individual cases, current data do not support the treatment of unruptured AVMs, which also present a low risk of bleeding in HHT patients. Screening for these AVMs is therefore controversial.Structured discussions, distinctions of different cerebrovascular abnormalities commonly grouped into an “AVM” bracket, and clear guidance by neurosurgical and neurointerventional radiology colleagues enabled the European Reference Network for Rare Vascular Disorders (VASCERN-HHT) to develop the following agreed Position Statement on cerebral screening:1) First, we emphasise that neurological symptoms suggestive of cerebral AVMs in HHT patients should be investigated as in general neurological and emergency care practice. Similarly, if an AVM is found accidentally, management approaches should rely on expert discussions on a case-by-case basis and individual risk-benefit evaluation of all therapeutic possibilities for a specific lesion.2) The current evidence base does not favour the treatment of unruptured cerebral AVMs, and therefore cannot be used to support widespread screening of asymptomatic HHT patients.3) Individual situations encompass a wide range of personal, cultural and clinical states. In order to enable informed patient choice, and avoid conflicting advice, particularly arising from non-neurovascular interpretations of the evidence base, we suggest that all HHT patients should have the opportunity to discuss knowingly brain screening issues with their healthcare provider.4) Any screening discussions in asymptomatic individuals should be preceded by informed pre-test review of the latest evidence regarding preventative and therapeutic efficacies of any interventions. The possibility of harm due to detection of, or intervention on, a vascular malformation that would not have necessarily caused any consequence in later life should be stated explicitly.We consider this nuanced Position Statement provides a helpful, evidence-based framework for informed discussions between healthcare providers and patients in an emotionally charged area.
- Open Access
- 1 January 2019
- Published by Stichting Nase in Rhinology journal
- Vol. 57 (4) , 242-251
Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series
Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic disorder, with a wide variety of clinical manifestations due to the presence of multiple arteriovenous manifestations. Severe bleeding from the gastrointestinal (GI) tract and/or epistaxis presents a significant problem in a subgroup of patients and systemic bevacizumab, an angiogenesis inhibitor, has been suggested to benefit these patients. To perform a review of the literature concerning the efficacy of systemic bevacizumab in treatment of bleeding from the nose or GI tract in patients with HHT, including patients from our own HHT-center. A literature review was performed using the guideline "Preferred Reporting Items for systematic Reviews and MetaAnalysis statement" (PRISMA). After careful selection, we finally analysed the results of eight case series and 33 case reports. Among 195 patients 171 (88%) had reduced bleeding after bevacizumab. Based on the literature review and data from our own case series, systemic bevacizumab is very promising as treatment for HHT patients with severe epistaxis and/or GI-bleeding. However, care should be taken using bevacizumab, a potent angiogenesis inhibitor; long-term side effects have not been studied in this population. A randomized controlled study is warranted to support the results in HHT patients.
- 1 January 2019
- Published by Stichting Nase in Rhinology journal
- Vol. 57 (4) , 242-251
Open AccessDoes severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series
Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic disorder, with a wide variety of clinical manifestations due to the presence of multiple arteriovenous manifestations. Severe bleeding from the gastrointestinal (GI) tract and/or epistaxis presents a significant problem in a subgroup of patients and systemic bevacizumab, an angiogenesis inhibitor, has been suggested to benefit these patients. To perform a review of the literature concerning the efficacy of systemic bevacizumab in treatment of bleeding from the nose or GI tract in patients with HHT, including patients from our own HHT-center. A literature review was performed using the guideline "Preferred Reporting Items for systematic Reviews and MetaAnalysis statement" (PRISMA). After careful selection, we finally analysed the results of eight case series and 33 case reports. Among 195 patients 171 (88%) had reduced bleeding after bevacizumab. Based on the literature review and data from our own case series, systemic bevacizumab is very promising as treatment for HHT patients with severe epistaxis and/or GI-bleeding. However, care should be taken using bevacizumab, a potent angiogenesis inhibitor; long-term side effects have not been studied in this population. A randomized controlled study is warranted to support the results in HHT patients.
- Open Access
- 19 September 2018
- Published by Springer Nature in BMC Nephrology
- Vol. 19 (1) , 238
Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion
Liver cirrhosis is characterized by avid sodium retention where the activation of the renin angiotensin aldosterone system (RAAS) is considered to be the hallmark of the sodium retaining mechanisms. The direct effect of angiotensin II (ANGII) on the AT-1 receptor in the proximal tubules is partly responsible for the sodium retention. The aim was to estimate the natriuretic and neurohumoral effects of an ANGII receptor antagonist (losartan) in the late phase of the disease in a rat model of liver cirrhosis. Bile duct ligated (BDL) and sham operated rats received 2 weeks of treatment with losartan 4 mg/kg/day or placebo, given by gastric gavage 5 weeks after surgery. Daily sodium and potassium intakes and renal excretions were measured. The renal sodium excretion decreased in the BDL animals and this was not affected by losartan treatment. At baseline the plasma renin concentration (PRC) was similar in sham and BDL animals, but increased urinary excretion of ANGII and an increase P-Aldosterone was observed in the placebo treated BDL animals. The PRC was more than 150 times higher in the losartan treated BDL animals (p < 0.001) which indicated hemodynamic impairment. Losartan 4 mg/kg/day did not increase renal sodium excretion in this model of liver cirrhosis, although the urinary ANGII excretion was increased. The BDL animals tolerated Losartan poorly, and the treatment induced a 150 times higher PRC.
- 19 September 2018
- Published by Springer Nature in BMC Nephrology
- Vol. 19 (1) , 238
Open AccessActivation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion
Liver cirrhosis is characterized by avid sodium retention where the activation of the renin angiotensin aldosterone system (RAAS) is considered to be the hallmark of the sodium retaining mechanisms. The direct effect of angiotensin II (ANGII) on the AT-1 receptor in the proximal tubules is partly responsible for the sodium retention. The aim was to estimate the natriuretic and neurohumoral effects of an ANGII receptor antagonist (losartan) in the late phase of the disease in a rat model of liver cirrhosis. Bile duct ligated (BDL) and sham operated rats received 2 weeks of treatment with losartan 4 mg/kg/day or placebo, given by gastric gavage 5 weeks after surgery. Daily sodium and potassium intakes and renal excretions were measured. The renal sodium excretion decreased in the BDL animals and this was not affected by losartan treatment. At baseline the plasma renin concentration (PRC) was similar in sham and BDL animals, but increased urinary excretion of ANGII and an increase P-Aldosterone was observed in the placebo treated BDL animals. The PRC was more than 150 times higher in the losartan treated BDL animals (p < 0.001) which indicated hemodynamic impairment. Losartan 4 mg/kg/day did not increase renal sodium excretion in this model of liver cirrhosis, although the urinary ANGII excretion was increased. The BDL animals tolerated Losartan poorly, and the treatment induced a 150 times higher PRC.
- 20 March 2017
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 77 (4) , 298-309
Internal dysregulation of the renin system in patients with stable liver cirrhosis
Sodium retention in cirrhosis is associated with changes in the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system (SNS), and the glomerular filtration rate (GFR). We hypothesized that in cirrhosis the acute reactions of RAAS and SNS to volume expansion are qualitatively intact, but occurring from elevated baseline levels. Acute cardiovascular, neurohumoral and renal responses to central blood volume changes were studied in cirrhotic patients and healthy controls. In patients, baseline plasma renin concentration (PRC) was elevated 5-fold compared to controls (p < .001); it increased during standing (+144%, p < .001) and remained elevated during subsequent sitting (+118%, p < .001). At baseline, plasma angiotensin II (pANGII) was not elevated significantly (14 ± 2 vs. 9 ± 2 pg/mL) in contrast to plasma aldosterone (pAldo, +160%, p < .001). During orthostatic RAAS activation, the rise in pAngII per unit increase in PRC was 0.04 pg AngII/mIU and 0.48 pg AngII/mIU in patients and controls, respectively (p < .001); similarly, the change in pAldo per unit change in pANGII was 3.6 in patients and 14.5 pg/pg in controls (p < .001). Plasma noradrenaline was elevated in the patients, but the dynamic changes were virtually identical to those of controls. During standing, abrupt decreases in renal blood flow (−63%, p < .001) and GFR (−42% p < .04) occurred only in patients. In conclusion, in stable cirrhosis, static and dynamic dysregulation exists within the RAAS; in the supine position pAngII levels are inappropriately low, and the AngII-mediated regulation of aldosterone secretion is severely impeded. In cirrhotic patients, profound reductions in renal blood flow and GFR occur during standing.
- 20 March 2017
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 77 (4) , 298-309
Internal dysregulation of the renin system in patients with stable liver cirrhosis
Sodium retention in cirrhosis is associated with changes in the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system (SNS), and the glomerular filtration rate (GFR). We hypothesized that in cirrhosis the acute reactions of RAAS and SNS to volume expansion are qualitatively intact, but occurring from elevated baseline levels. Acute cardiovascular, neurohumoral and renal responses to central blood volume changes were studied in cirrhotic patients and healthy controls. In patients, baseline plasma renin concentration (PRC) was elevated 5-fold compared to controls (p < .001); it increased during standing (+144%, p < .001) and remained elevated during subsequent sitting (+118%, p < .001). At baseline, plasma angiotensin II (pANGII) was not elevated significantly (14 ± 2 vs. 9 ± 2 pg/mL) in contrast to plasma aldosterone (pAldo, +160%, p < .001). During orthostatic RAAS activation, the rise in pAngII per unit increase in PRC was 0.04 pg AngII/mIU and 0.48 pg AngII/mIU in patients and controls, respectively (p < .001); similarly, the change in pAldo per unit change in pANGII was 3.6 in patients and 14.5 pg/pg in controls (p < .001). Plasma noradrenaline was elevated in the patients, but the dynamic changes were virtually identical to those of controls. During standing, abrupt decreases in renal blood flow (−63%, p < .001) and GFR (−42% p < .04) occurred only in patients. In conclusion, in stable cirrhosis, static and dynamic dysregulation exists within the RAAS; in the supine position pAngII levels are inappropriately low, and the AngII-mediated regulation of aldosterone secretion is severely impeded. In cirrhotic patients, profound reductions in renal blood flow and GFR occur during standing.
- 15 February 2015
- Published by Wiley in Liver International
- Vol. 35 (9) , 2072-2078
Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta‐analysis
Background & Aims: Patients with cirrhosis and alcoholic hepatitis are often malnourished and have a superimposed stress metabolism, which increases nutritional demands. We performed a systematic review on the effects of nutritional therapy vs. no intervention for patients with cirrhosis or alcoholic hepatitis.Methods: We included trials on nutritional therapy designed to fulfil at least 75% of daily nutritional demand. Authors extracted data in an independent manner. Random‐effects and fixed‐effect meta‐analyses were performed and the results expressed as risk ratios (RR) with 95% confidence intervals (CI). Sequential analyses were performed to evaluate the risk of spurious findings because of random and systematic errors. Subgroup and sensitivity analyses were performed to evaluate the risk of bias and sources of between trial heterogeneity.Results: Thirteen randomized controlled trials with 329 allocated to enteral (nine trials) or intravenous (four trials) nutrition and 334 controls. All trials were classed as having a high risk of bias. Random‐effects meta‐analysis showed that nutritional therapy reduced mortality 0.80 (95% CI, 0.64 to 0.99). The result was not confirmed in sequential analysis. Fixed‐effect analysis suggested that nutrition prevented overt hepatic encephalopathy (0.73; 95% CI, 0.55 to 0.96) and infection (0.66; 95% CI, 0.45 to 0.98, respectively), but the results were not confirmed in random‐effects analyses.Conclusion: Our review suggests that nutritional therapy may have beneficial effects on clinical outcomes in cirrhosis and alcoholic hepatitis. High‐quality trials are needed to verify our findings.
- 15 February 2015
- Published by Wiley in Liver International
- Vol. 35 (9) , 2072-2078
Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta‐analysis
Background & Aims: Patients with cirrhosis and alcoholic hepatitis are often malnourished and have a superimposed stress metabolism, which increases nutritional demands. We performed a systematic review on the effects of nutritional therapy vs. no intervention for patients with cirrhosis or alcoholic hepatitis.Methods: We included trials on nutritional therapy designed to fulfil at least 75% of daily nutritional demand. Authors extracted data in an independent manner. Random‐effects and fixed‐effect meta‐analyses were performed and the results expressed as risk ratios (RR) with 95% confidence intervals (CI). Sequential analyses were performed to evaluate the risk of spurious findings because of random and systematic errors. Subgroup and sensitivity analyses were performed to evaluate the risk of bias and sources of between trial heterogeneity.Results: Thirteen randomized controlled trials with 329 allocated to enteral (nine trials) or intravenous (four trials) nutrition and 334 controls. All trials were classed as having a high risk of bias. Random‐effects meta‐analysis showed that nutritional therapy reduced mortality 0.80 (95% CI, 0.64 to 0.99). The result was not confirmed in sequential analysis. Fixed‐effect analysis suggested that nutrition prevented overt hepatic encephalopathy (0.73; 95% CI, 0.55 to 0.96) and infection (0.66; 95% CI, 0.45 to 0.98, respectively), but the results were not confirmed in random‐effects analyses.Conclusion: Our review suggests that nutritional therapy may have beneficial effects on clinical outcomes in cirrhosis and alcoholic hepatitis. High‐quality trials are needed to verify our findings.